Core Viewpoint - The Beijing Municipal Drug Administration has announced the results of its first drug quality safety information release for 2026, highlighting non-compliant drugs identified during supervision and inspection [3]. Group 1: Non-compliant Drugs - A list of non-compliant drugs has been published, detailing the names, production companies, batch numbers, specifications, and inspection results [3]. - Specific drugs mentioned include "Kuan Dong Hua" from Hubei Daodi Medicinal Materials, which failed to meet standards regarding appearance and content [3]. - "Jin Sang Kai Yin" from Xi'an Beilin Pharmaceutical also showed non-compliance related to microbial limits [3]. Group 2: Regulatory Actions - Relevant units have taken necessary control measures against the non-compliant products and are pursuing legal actions against violations [3]. - The announcement emphasizes the importance of adhering to the standards set forth in the 2020 edition of the Chinese Pharmacopoeia [3].
北京市药品监督管理局关于发布2026年第一期药品质量安全信息的通告
Xin Lang Cai Jing·2026-02-25 06:37